Table 1.
Clinical characteristics and laboratory and echocardiographic findings of the groups.
| COVID-19 patients (n=40) | Control group (n=40) | p | |
|---|---|---|---|
| Age, years | 54±11 | 52±13 | NS |
| Gender, male, n (%) | 26 (65) | 24 (60) | NS |
| Smoking, n (%) | 12 (30) | 10 (25) | NS |
| Hypertension, n (%) | 8 (20) | 6 (15) | NS |
| Diabetes, n (%) | 6 (15) | 4 (10) | NS |
| Systolic BP, mmHg | 124.6±8.2 | 123.6±6.8 | NS |
| Diastolic BP, mmHg | 73.6± 6.0 | 72.5±4.6 | NS |
| Heart rate, beats/min | 75.4±12 | 73.6± 16 | NS |
| LVEF, % | 60.3± 3.2 | 61.9±4.8 | NS |
| MPI | 0.56±0.09 | 0.41±0.06 | <0.001 |
| IRT, ms | 112.3±13.4 | 90.6±11.2 | <0.001 |
| ICT, ms | 44.3±7.8 | 41.8±8.7 | NS |
| E/A | 1.53±0.7 | 1.21±0.3 | <0.001 |
| ET, ms | 279.6±20.3 | 299.6±34.7 | <0.001 |
| DT, ms | 182.1±30.6 | 160.8±42.7 | 0.003 |
| Hb, g/dl | 13.2±1.6 | 13.8±1.7 | NS |
| CK, IU/l | 216.3±125.4 | 198.2±113.6 | NS |
| LDH, IU/l | 486.8±118.6 | 316.4±108.9 | 0.002 |
| cTnI, ng/ml | 0.96±0.12 | 0.10±0.01 | <0.001 |
| Creatinine, mg/dl | 1.2±0.6 | 1.0±0.7 | NS |
| WBC, 103/μl | 12.3±4.7 | 7.0±2.6 | <0.001 |
| Neutrophil count, 103/μl | 9.7±6.2 | 4.2±1.5 | <0.001 |
| Lymphocyte count, 103/μl | 0.9±0.2 | 2.8±0.6 | <0.001 |
BP: blood pressure; CK: creatinine kinase; cTnI: cardiac troponin I; DT: deceleration time; E/A:transmitral early to late peak velocity ratio; ET: ejection time; ICT: isovolumic contraction time; IRT: isovolumic relaxation time; Hb: hemoglobin; LDH: lactate dehydrogenase; LVEF: left ventricular ejection fraction; MPI: myocardial performance index; NS: not significant; WBC: white blood cell count.